Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibrexafungerp vs Fluconazole for Invasive Candidiasis (MARIO)
NCT05178862Phase 3Terminated
- Sponsor
- SCYNEXIS, Inc.
- Start
- Aug 2022
- Primary completion
- Nov 2025
- Modality
- Allosteric Modulators
- Countries
- 13
01
Overview
Phase 3, randomised, double-blind trial of ibrexafungerp in invasive candidiasis and candidemia (2 arms), sponsored by SCYNEXIS, Inc. Primary endpoints: All-cause Mortality at 30 days and Global Response at End of Treatment at 6 weeks. Started Aug 2022; status: terminated.
02
Drugs
ibrexafungerp
03
Conditions
invasive candidiasiscandidemia
Beyond the preview
Go deeper on NCT05178862.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05178862.